Education and Training
- Fellowship, Medical Oncology, Yale University, 2006 - 2009
- Residency, Internal Medicine, Penn State Milton S. Hershey Medical Center, 2002 - 2005
- D.O., New York Institute of Technology, College of Osteopathic Medicine, 2001
Esagian, Stepan M., Ali Raza Khaki, Leonidas N. Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Joseph J. Park, et al. “Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.” Bju Int, February 8, 2021. https://doi.org/10.1111/bju.15324.
Wang, Xinning, Aditi Shirke, Ethan Walker, Rongcan Sun, Gopolakrishnan Ramamurthy, Jing Wang, Lingpeng Shan, et al. “Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.” Cancers (Basel) 13, no. 3 (January 22, 2021). https://doi.org/10.3390/cancers13030417.
Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.
Shieh, Alice C., Ezgi Guler, David Pfau, Ethan Radzinsky, Daniel A. Smith, Christopher Hoimes, Nikhil H. Ramaiya, and Sree Harsha Tirumani. “Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy.” Abdom Radiol (Ny) 45, no. 10 (October 2020): 3028–35. https://doi.org/10.1007/s00261-019-02334-3.
Ansari-Gilani, Kianoush, Sree Harsha Tirumani, Daniel A. Smith, Ariel Nelson, Asrar Alahmadi, Christopher J. Hoimes, and Nikhil H. Ramaiya. “Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients.” Emerg Radiol 27, no. 4 (August 2020): 455–60. https://doi.org/10.1007/s10140-020-01765-6.
Miller, Natalie J., Ali Raza Khaki, Leonidas N. Diamantopoulos, Mehmet A. Bilen, Victor Santos, Neeraj Agarwal, Rafael Morales-Barrera, et al. “Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.” J Urol 204, no. 1 (July 2020): 63–70. https://doi.org/10.1097/JU.0000000000000761.
Khaki, Ali Raza, Ang Li, Leonidas N. Diamantopoulos, Mehmet A. Bilen, Victor Santos, John Esther, Rafael Morales-Barrera, et al. “Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.” Cancer 126, no. 6 (March 15, 2020): 1208–16. https://doi.org/10.1002/cncr.32645.
Flaig, Thomas W., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam Chang, et al. “Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 3 (March 2020): 329–54. https://doi.org/10.6004/jnccn.2020.0011.
Antonarakis, Emmanuel S., Josep M. Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J. Hoimes, Ulka Vaishampayan, et al. “Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.” J Clin Oncol 38, no. 5 (February 10, 2020): 395–405. https://doi.org/10.1200/JCO.19.01638.